A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

118

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions

Hypercholesterolemia

Interventions

DRUG

CAT-2054

DRUG

Placebo

DRUG

CAT-2054-C

DRUG

Atorvastatin

Trial Locations (1)

Spaulding Clinical Research, West Bend